UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): April 23,
2018
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
001-36498
|
|
86-1032927
|
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408) 973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01
Other Events.
On
April 21, 2018, the China Food and Drug Administration (CFDA)
Center for Drug Evaluation (CDE) posted on its website acceptance
of the Investigative New Drug (IND) application for chimeric
antigen receptor T cells (CAR-T) cancer therapies in treating
patients with adult acute lymphoblastic leukemia (ALL) submitted by
Cellular Biomedicine Group (Shanghai) Ltd. and Shanghai Cellular
Biopharmaceutical Group Ltd., two of our wholly-owned subsidiaries
of Cellular Biomedicine Group, Inc. (collectively, the Company).
There can be no assurance that the application will ultimately be
approved.
In
December 2017, the Chinese government issued clinical trial
guidelines concerning development and testing of cell therapy
products, including immune cell therapies such as CAR-T cell
therapeutics. The Company currently has ongoing CAR-T Phase I
clinical trials in China; CARD-1 (CAR-T Against DLBCL) for NHL and
Diffuse Large B-cell Lymphoma (DLBCL), and CALL-1 (CAR-T against
Acute Lymphoblastic Leukemia) CD19 CAR-T therapy utilizing its
optimized proprietary C-CAR011 construct for the treatment of
patients with relapsed or refractory (r/r) CD19+ B-cell
ALL.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
|
|
Date:
April 23, 2018
|
By:
|
/s/ Bizuo
(Tony) Liu
|
|
|
|
|
Bizuo
(Tony) Liu
|
|
|
|
|
Chief
Executive Officer
|
|
|
|
|
|
|